Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474678 | 1.00 | HSD11B1 (0.48) | HSD11B1LMNAHRH3CYP2D6GRM5 | |
| SCHEMBL10072280 | 0.90 | HSD11B1 (0.47) | HSD11B1LMNAHRH3CYP2D6FDFT1 | |
| SCHEMBL474767 | 0.81 | HSD11B1 (0.40) | HSD11B1CYP2D6 | |
| SCHEMBL474724 | 0.78 | HSD11B1 (0.48) | HSD11B1LMNAHRH3CYP2D6FDFT1 | |
| SCHEMBL474723 | 0.78 | HSD11B1 (0.48) | HSD11B1LMNAHRH3CYP2D6FDFT1 | |
| SCHEMBL474725 | 0.78 | HSD11B1 (0.48) | HSD11B1LMNAHRH3CYP2D6FDFT1 | |
| SCHEMBL210102 | 0.76 | HSD11B1 (0.48) | HSD11B1LMNAHRH3CYP2D6FDFT1 | |
| SCHEMBL2989845 | 0.76 | HSD11B1 (0.48) | HSD11B1LMNAHRH3CYP2D6FDFT1 | |
| SCHEMBL209337 | 0.76 | HSD11B1 (0.48) | HSD11B1LMNAHRH3CYP2D6FDFT1 | |
| SCHEMBL209338 | 0.76 | HSD11B1 (0.48) | HSD11B1LMNAHRH3CYP2D6FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049475-B1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998999-B2 | Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-08-16 | — | — | US | disclosed |
| US-7816349-B2 | Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2029529-B1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090239911-A1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-09-24 | — | — | US | disclosed |
| EP-2049475-A1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090069326-A1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| EP-2029529-A1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007127704-A1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127693-A1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069326-A1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885LMNA 2960/4885HRH3 2933/4885 |
| US-20090239911-A1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885LMNA 2280/4885HRH3 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.